ABVC Q3 10-Q: $11,294 Cash, $5.79M Working Capital Deficit, Going-Concern Doubt
ABVC sits 41% above its 52-week low of $0.707 on light trading volume (0.4× avg).
Summary
ABVC's Q3 10-Q shows $11,294 of cash, a $5.79 million working capital deficit and going-concern doubt, cushioned only by the $3.39 million convertible note deal that closed October 30, 2026. The quarter also carried a $795,950 revenue restatement and a $7.0 million intangible impairment.
Key Events · Earnings and Guidance · ABVC
-
Going-Concern Doubt on $11,294 Cash
Cash and equivalents fell to $11,294 at September 30, 2026 from $681,480 at December 31, 2025, with a $5,788,170 working capital deficit and $1,577,567 of nine-month operating cash burn. The filing states these conditions raise substantial doubt about the ability to continue as a going concern.
-
$3.39M Note Deal Is the Only Near-Term Funding
The October 30, 2026 private placement of 17.5% OID senior convertible notes carried $4,106,060 principal for $3,387,500 gross and $2,216,927 net after fees and the $625,000 Lind settlement. Notes convert at 85% of the three-day VWAP with a $0.20 floor and mature June 30, 2027.
-
$795,950 of 2025 Licensing Revenue Reversed
The 10-Q restates nine-month 2025 results, reversing $560,000 from OncoX, $200,000 from ForSeeCon and $35,950 of OncoX operating funds because the cash was indirectly funded by ABVC's related party BioFirst and failed ASC 606 conditions.
-
Material Weakness and Advisor Termination
Disclosure controls were not effective at September 30, 2026 due to the previously disclosed material weakness. The company also terminated an external advisor after identifying undisclosed regulatory or disciplinary matters, with no material impact on prior financials.
Analysis · ABVC · Life Sciences
With $11,294 of cash at September 30, a $5,788,170 working capital deficit and $1,577,567 burned in operations over nine months, the filing states these conditions raise substantial doubt about ABVC's ability to continue as a going concern. The only near-term lifeline is the $3.39 million convertible note private placement that closed October 30, 2026, which netted $2,216,927 after fees and the $625,000 Lind settlement. The quarter also brought a restatement reversing $795,950 of 2025 licensing revenue that management concluded had indirectly come from the company itself, a full $7.0 million impairment of AiBtl intangibles, and a continuing material weakness in internal controls. Existing holders face heavy future dilution: the new notes convert at 85% of VWAP with a $0.20 floor, and the 2026 equity plan added 5,173,372 shares to the award pool.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABVC was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $0.71 to $3.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.